Several studies have reported that IDH mutations do not affect the prognosis in AML, whereas other studies have found that IDH mutations are associated with an increased or decreased risk of relapse when compared with IDH wild-type patients.6, 7. The gene discussed is IDH2; the disease is acute myeloid leukemia.